May 21, 2026
The Developing Science of Gene Therapy
Current and future applications of retinal gene therapy may reshape treatment for noninherited retinal diseases.
2026 Retina World Congress annual meeting
May 14, 2026 - May 17, 2026
Fort Lauderdale, Florida
The 2026 Retina World Congress meeting, described as "Redefining retina innovation and impact on a global scale, will be held May 14-17, 2026, at the Marriott Harbor Beach Resort in Fort Lauderdale, Florida.
Related Content
May 19, 2026
Phase 3 Ixo-Vec Program Advances
The ARTEMIS and AQUARIUS studies will evaluate the intravitreal gene therapy for neovascular AMD, after earlier trials demonstrated durable treatment effects.
May 18, 2026
Early PPV With ILM Peeling Shows Durable Outcomes in Selected DME Patients
Surgery may offer an option for patients unlikely to adhere to frequent anti-VEGF treatment schedules.
May 18, 2026
A Critical Eye on GLP-1 Receptor Agonists
Emerging evidence suggests some retinal safety signals may be real, while others remain uncertain.
May 18, 2026
Investigational OCTA Devices Show Promise in Diabetic Disease Assessment
Patricio G. Schlottmann, MD, discussed investigational imaging systems that may improve detection of peripheral diabetic retinal disease.
May 18, 2026
TEASE Program Builds Case for Gildeuretinol in Stargardt
The TEASE clinical program has shown reductions in atrophic lesion growth. A phase 3 trial, NORTHSTAR, is currently enrolling.
May 16, 2026
Diagnosing and Treating Ocular Lymphoma
At the 2026 Retina World Congress meeting, Kapil Mishra, MD, explained how new diagnostic tools and treatment agents are refining management of PVRL.
May 15, 2026
Avoid Aches and Pains in Retina Practice
Simple adjustments to posture, equipment positioning, and workflow can help retina specialists prevent chronic pain.
May 15, 2026
EYP-1901 Approaches a Pivotal Fall
At Retina World Congress, Ashkan M. Abbey, MD, FASRS, FAAO, reviewed the Duravyu clinical development program. Top-line data from the phase 3 LUGANO and LUCIA trials in wet AMD are expected later this year.
May 15, 2026
COVID-19, Vaccines, and Retinal Vascular Disease
A global systematic review of 173 studies found differing associations between COVID-19 infection and vaccination and retinal vascular events, with retinal artery occlusion more common after infection and retinal vein occlusion more common after vaccination.
May 15, 2026
Can Gene Therapy Deliver Durability?
At Retina World Congress, David A. Eichenbaum, MD, examined whether late-stage intravitreal gene therapies can reduce injection burden in nAMD.
May 15, 2026
Recognizing MacTel Masquerades
Imaging features such as retinal thinning and ellipsoid zone loss can help differentiate MacTel from AMD and related retinal diseases.
May 15, 2026
What RVO May Reveal About Systemic Health
TriNetX data presented at Retina World Congress linked BRVO and CRVO with increased risks of stroke, myocardial infarction, and carotid disease.
May 15, 2026
Can Home OCT Change nAMD Monitoring?
Courtney Crawford, MD, highlighted clinical data and the Protocol AO trial evaluating home OCT’s impact on monitoring and treatment decisions in AMD.
May 14, 2026
Managing an Aggressive Case of Placoid Chorioretinopathy
At Retina World Congress, Arthi Venkat, MD, MS, explained how to differentiate ampiginous chorioretinitis from infectious retinitis in a patient with rapid vision loss.
May 14, 2026
FDA Updates: Retina Trials and Regulatory Pathways
William M. Boyd, MD, director of the FDA’s Division of Ophthalmology, discussed the agency’s evolving approaches to clinical evidence, trial design, and expedited regulatory pathways at the 2026 Retina World Congress meeting.
May 7, 2026
2026 Retina World Congress Preview
Baruch D. Kuppermann, MD, PhD, highlights the global focus and broad retina agenda of the upcoming Retina World Congress meeting in Fort Lauderdale.